EBS - Emergent BioSolutions Inc.
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 8.17 |
| Open | 8.24 |
| Bid | 8.06 x 1400 |
| Ask | 8.08 x 800 |
| Day's Range | 8.03 - 8.57 |
| 52 Week Range | 7.74 - 36.14 |
| Volume | |
| Avg. Volume | 1,814,608 |
| Market Cap | 406.61M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.07 |
| Earnings Date | Jul 31, 2023 - Aug 04, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.75 |
Fair Value
Related Research
ZacksNew Strong Sell Stocks for May 17th
BIDU, EBS and FRO have been added to the Zacks Rank #5 (Strong Sell) List on May 17, 2023.
Motley FoolWhy Emergent BioSolutions Stock Inched Slightly Higher Today
Emergent BioSolutions (NYSE: EBS) has been quite the up-and-down stock of late. On Monday, it had an up session on the market, creeping northward by 1.2% and exceeding the S&P 500's gain of 0.3%. The buyer is Denmark-headquartered peer Bavarian Nordic, which has handed over $270 million for the set of assets.
GlobeNewswireEmergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it has completed the sale of its travel health business to Bavarian Nordic (OMX: BAVA). At closing Emergent received $270 million, subject to customary closing adjustments, and may receive up to an additional $110 million in potential future milestone payments. With the transaction closed, Bavarian Nordic has acquired the rights to Vivotif®, the licensed typhoid vaccine, and Vaxchora®, the licen
- GlobeNewswire
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 25, 2023 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the proxy materials, stockholders of record are eligible to participate in and ask questions during the Virtual Annual Meeting by visiting www.virtualshareholdermeeting.com/EBS2023
ZacksEmergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat
Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.
- Thomson Reuters StreetEvents
Q1 2023 Emergent BioSolutions Inc Earnings Call
Q1 2023 Emergent BioSolutions Inc Earnings Call
American City Business JournalsEmergent BioSolutions’ share price sinks following Q1 earnings. But it’s betting big on Narcan.
The company is prepping over-the-counter sales of the opioid overdose drug — and recently named its price.
Motley FoolEmergent BioSolutions (EBS) Q1 2023 Earnings Call Transcript
My name is Bob Burrows. Thank you for joining us today as we discuss the operational and financial results for the first quarter of 2023. As is customary, today's call is open to all participants in the call is being recorded and is copyrighted by Emergent BioSolutions.
ZacksEmergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -89.82% and 15.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Emergent BioSolutions Reports Financial Results For First Quarter 2023
Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101MUpdates FY 2023 guidance and provides initial Q2 2023 guidance GAITHERSBURG, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2023. Among the highlights, Emergent has received from the U.S. government Notices of Intent to Purchase medical countermeasures to combat smallpox
ZacksBiotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More
Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.
ZacksEmergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?
Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Investing.com
Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recap
By Vlad Schepkov
- Reuters
Emergent aims to price over-the-counter Narcan at about $50
Contract drugmaker Emergent BioSolutions Inc said on Thursday it is aiming to price the over-the-counter (OTC) version of its opioid overdose reversal drug Narcan at around $50 per carton. The OTC version will become available at U.S. stores and online retailers later this summer, while the currently available prescription nasal spray carries a wholesale price tag of $125 per carton. Emergent's statement comes nearly a month after the U.S. Food and Drug Administration allowed Narcan to be sold over-the-counter, allowing for easier availability of the life-saving medication.
- GlobeNewswire
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second quarter of 2023, and financial outlook for full year 2023. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent’s website. To partici
ZacksLooking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Barrons.comEmergent Biosolutions Upgraded After FDA Approves Narcan OTC Sales
The biotech plans to launch the over-the-counter product this summer, beating competitors to the punch.
Motley FoolWhy Emergent BioSolutions Stock Is Soaring Today
Shares of Emergent BioSolutions (NYSE: EBS) were soaring 11% higher as of 11:13 a.m. ET on Thursday. The big gain came after the Food and Drug Administration (FDA) approved the company's Narcan on Wednesday as an over-the-counter (OTC) treatment for opioid overdoses. Emergent's Narcan has been available since 2016 as a prescription drug for opioid overdose.
ZacksEmergent Biosolutions (EBS) Surges 5.1%: Is This an Indication of Further Gains?
Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Barrons.comFDA Approves Narcan for Over-the-Counter Use. What It Means for Emergent Bio’s Stock.
Narcan, a standard treatment for opioid overdoses, will become available in U.S. retail stores later this year, as part of health officials’ efforts to reduce the number of fatal overdoses. The move should also pave the way for growing sales for Emergent Biosolutions which produces Narcan. On Wednesday, the Food and Drug Administration approved Narcan, a naloxone hydrochloride nasal spray, for over-the-counter use.
BenzingaFDA Approves First OTC Naloxone Nasal Spray For Opioid Overdose
The FDA has approved Emergent BioSolutions Inc's (NYSE: EBS) Narcan, 4 milligrams (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription use – the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. The move paves the way for the medication to reverse an opioid overdose to be sold directly to consumers in drug stores, convenienc
ZacksEmergent Biosolutions (EBS) Down 28.1% Since Last Earnings Report: Can It Rebound?
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Wall Street JournalFDA Makes Overdose-Reversal Drug Narcan Available Over-the-Counter
For the first time since the opioid crisis began, people will be able to buy medication on retail shelves to reverse an overdose.
- GlobeNewswire
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
NARCAN® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening accessExpected over-the-counter availability is anticipated by late summer of this year GAITHERSBURG, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® Naloxone HCl Nasal Spray 4 m